MoonLake Q3 R&D expenses rise 37% quarter over quarter to $68.9 million

PUBT · 1d ago
MoonLake Q3 R&D expenses rise 37% quarter over quarter to $68.9 million
  • MoonLake’s third-quarter 2026 R&D expenses rose 37% quarter-over-quarter to $68.9 million, while general and administrative expenses fell to $11 million.
  • Cash, cash equivalents and short-term marketable debt securities totaled $498.5 million at September 30, with cash runway expected through mid-2028.
  • A sonelokimab application for hidradenitis suppurativa was submitted to the FDA; a US launch is expected in H2 2027, if approved.
  • Sonelokimab 60 mg with induction met all Week 16 clinical endpoints in IZAR-1; initial IZAR-2 results are expected in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040700PRIMZONEFULLFEED1001301616) on November 04, 2026, and is solely responsible for the information contained therein.